Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | La Merie | Competitor Analysis: Antibody-Drug Conjugates (ADC)

Competitor Analysis: Antibody-Drug Conjugates (ADC)

The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug payload for treatment of cancer as of June 2009.

The newer generations of antibodies are characterized by having increased effector functions. This can be achieved either by engineering the antibody itself to optimize Fc effector functions such as ADCC and CDC, or adding payload functions to the antibody by incorporating a second targeting specificity to recruit immune effector cells or fusing it with toxins or cytokines. A more mature and advanced technology is conjugating the antibody with a cytotoxic drug moiety. The basic principle of antibody-drug conjugates is to use the antibody moiety for targeting the tumor and for tumor-specific delivery of a cytotoxic agent. One such antibody-drug conjugate (ADC) is already commercially available while other earlier projects were hampered by a small therapeutic window, mainly due to systemic toxicity caused by the premature release of the cytotoxic drug from an instable linker between antibody and drug.

The most advanced technologies today offer stable linker technology and cytotoxic prodrugs which only become effective once the conjugate has entered the tumor cell by endocytosis and the drug cleared by proteolytic digestion from the conjugate inside the cell. A high tumor specific expression of the target is a prerequisite for lowering the systemic side effects of the ADC. The therapeutic window further can be improved if the cytotoxic agent is a prodrug only activated by intracellular enzymes. Further advances have been made by selecting cytotoxic drugs without drug resistance, by using peptide linkers instead of chemical moieties and by

At present, two further antibody-drug conjugates are in pivotal clinical studies and at least four different ADC molecules in phase II clinical evaluation. The early stage clinical pipeline consists of at least seven different phase I ADCs and further six in IND enabling studies. The preclinical pipeline is rather full by more than 9 ADCs in advanced preclinical phase and many more in earlier stages.

The report includes a compilation of current active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

Index

Antibody-Drug Conjugates (ADC)

Other Immunoconjugates in Oncology

Corporate Antibody-Drug Conjugate R&D Pipelines

About La Merie

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Publisher: La Merie

Product Line: Competitor Analysis

Pages: 37

Release Date: June of 2009

Format: PDF

Product Code: LMCA0043

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions